Proinflammatory cytokines have been proposed as potential targets for the management of RITIs.115 Clinically, neutralizing antibodies that can block IL-17, IL-17RA, and/or IL-17RC signals have been widely used and shown a reduced severity and improved remission in inflammatory diseases such as inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus.30,116. This evidence concerns the gene IL17RA and inflammatory bowel disease.